KR20180102052A - 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 - Google Patents

조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 Download PDF

Info

Publication number
KR20180102052A
KR20180102052A KR1020187013668A KR20187013668A KR20180102052A KR 20180102052 A KR20180102052 A KR 20180102052A KR 1020187013668 A KR1020187013668 A KR 1020187013668A KR 20187013668 A KR20187013668 A KR 20187013668A KR 20180102052 A KR20180102052 A KR 20180102052A
Authority
KR
South Korea
Prior art keywords
amino
pyrrolidine
hydroxy
carboxamide
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187013668A
Other languages
English (en)
Korean (ko)
Inventor
조셉 알. 모스칼
허버트 멜처
Original Assignee
노오쓰웨스턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티 filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20180102052A publication Critical patent/KR20180102052A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187013668A 2015-10-16 2016-10-14 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 Ceased KR20180102052A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242633P 2015-10-16 2015-10-16
US62/242,633 2015-10-16
PCT/US2016/057071 WO2017066590A1 (en) 2015-10-16 2016-10-14 Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder

Publications (1)

Publication Number Publication Date
KR20180102052A true KR20180102052A (ko) 2018-09-14

Family

ID=57178579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187013668A Ceased KR20180102052A (ko) 2015-10-16 2016-10-14 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용

Country Status (10)

Country Link
US (1) US20180325893A1 (enExample)
EP (1) EP3362080A1 (enExample)
JP (2) JP2018530593A (enExample)
KR (1) KR20180102052A (enExample)
CN (1) CN108601814A (enExample)
AU (2) AU2016340080A1 (enExample)
BR (1) BR112018007681A2 (enExample)
CA (1) CA3002070A1 (enExample)
MX (1) MX2018004553A (enExample)
WO (1) WO2017066590A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060843A (ko) 2019-11-19 2021-05-27 뉴트라팜주식회사 기억력 및 인지기능 개선, 조현병 예방, 치료 또는 개선용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
US20200199173A1 (en) * 2017-07-28 2020-06-25 Naurex, Inc. Process and intermediates for synthesis of peptide compounds
BR112020009310A2 (pt) 2017-11-14 2020-10-13 Sk Biopharmaceuticals Co., Ltd. combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia.
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
US20220024976A1 (en) * 2019-01-11 2022-01-27 Naurex Inc. Salt and crystalline forms of rapastinel

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
WO2006066121A2 (en) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP2485751B1 (en) * 2009-10-05 2014-05-21 Northwestern University GLYX-13 for use in a method of treating refractory depression
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX357761B (es) * 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
WO2013080046A1 (en) * 2011-12-02 2013-06-06 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
EP2906722A4 (en) * 2012-10-12 2016-07-20 Univ Northwestern METHOD FOR IDENTIFYING COMPOUNDS FOR THE TREATMENT OF DEPRESSIONS AND RELATED DISEASES
US20160345855A1 (en) * 2013-12-13 2016-12-01 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
BR112016025910A8 (pt) * 2014-05-06 2021-07-13 Univ Northwestern uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
KR20170040351A (ko) * 2014-08-14 2017-04-12 노렉스, 인크. Nmda 조절인자를 사용하여 우울증을 치료하는 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060843A (ko) 2019-11-19 2021-05-27 뉴트라팜주식회사 기억력 및 인지기능 개선, 조현병 예방, 치료 또는 개선용 조성물

Also Published As

Publication number Publication date
RU2018116882A3 (enExample) 2020-02-18
US20180325893A1 (en) 2018-11-15
EP3362080A1 (en) 2018-08-22
CA3002070A1 (en) 2017-04-20
JP2022140441A (ja) 2022-09-26
BR112018007681A2 (en) 2018-11-06
CN108601814A (zh) 2018-09-28
AU2016340080A1 (en) 2018-05-10
AU2023216827A1 (en) 2023-09-07
JP2018530593A (ja) 2018-10-18
MX2018004553A (es) 2019-04-15
WO2017066590A1 (en) 2017-04-20
RU2018116882A (ru) 2019-11-18

Similar Documents

Publication Publication Date Title
AU2019204073B2 (en) NMDA receptor modulators and uses thereof
AU2023216827A1 (en) Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorder
US10195179B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
AU2014212485C1 (en) Spiro-lactam NMDA receptor modulators and uses thereof
AU2014212487C1 (en) Spiro-lactam NMDA receptor modulators and uses thereof
KR20170013890A (ko) Nmdar 조절 화합물의 조합물
KR20150110784A (ko) 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2017201283A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JP2020176124A (ja) Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
RU2802972C2 (ru) Фармацевтическая комбинация атипичного антипсихотика и модулятора nmda для лечения шизофрении, биполярного расстройства, когнитивного нарушения и клинической депрессии

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211013

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240102

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D